Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma

Cancer, EarlyView.


from Cancer via ola Kala on Inoreader https://ift.tt/2rfL1Xo
via IFTTT